Biomarker analysis in patients with steroid-refractory/dependent chronic graft-vs-host disease treated with ruxolitinib or best available therapy in the randomized phase 3 REACH3 study

被引：0

作者：

Locatelli, F. ^{[1
]}

Zeiser, R. ^{[2
]}

Teshima, T. ^{[3
]}

Prahallad, A. ^{[4
]}

Sinclair, K. ^{[4
]}

Stefanelli, T. ^{[4
]}

Lee, S. J. ^{[5
]}

机构：

[1] Sapienza Univ Rome, IRCCS, Osped Pediat Bambino Gesu, Rome, Italy

[2] Univ Freiburg, Freiburg, Germany

[3] Hokkaido Univ, Fac Med, Sapporo, Hokkaido, Japan

[4] Novartis Pharma AG, Basel, Switzerland

[5] Fred Hutchinson Canc Res Ctr, 1124 Columbia St, Seattle, WA 98104 USA

来源：

BONE MARROW TRANSPLANTATION | 2022年 / 57卷 / SUPPL 1期

关键词：

D O I：

暂无

中图分类号：

Q6 [生物物理学];

学科分类号：

071011 ;

摘要：

O054

引用

页码：41 / 42

页数：2

共 50 条

[1] Ruxolitinib vs Best Available Therapy in Patients With Steroid-Refractory/Steroid-Dependent Chronic Graft-Vs-Host Disease: Primary Findings From the Phase 3, Randomized REACH3 Study
不详
CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2021, 19 (02) : 6 - 8
[2] Ruxolitinib (RUX) Vs Best Available Therapy (BAT) in Patients with Steroid-Refractory/Steroid-Dependent Chronic Graft-Vs-Host Disease (cGVHD): Primary Findings from the Phase 3, Randomized REACH3 Study
Zeiser, Robert
Polverelli, Nicola
Ram, Ron
Hashmi, Shahrukh K.
Chakraverty, Ronjon
Flowers, Mary E. D.
Dawkins, Fitzroy
Hollaender, Norbert
Gowda, Maanasa
Stefanelli, Tommaso
Lee, Stephanie J.
Teshima, Takanori
Locatelli, Franco
BLOOD, 2020, 136
[3] Ruxolitinib Vs Best Available Therapy in Patients With Steroid-Refractory/Dependent Chronic GRAFT-VS-HOST Disease (CGVHD): Subgroup Analyses of Overall Response Rate in The Phase 3 Reach3 Trial
Locatelli, Franco
Polverelli, Nicola
Ram, Ron
Hashmi, Shahrukh K.
Chakraverty, Ronjon
Middeke, Jan Moritz
Musso, Maurizio
Giebel, Sebastian
Uzay, Ant
Ayuk, Francis Ayuketang
Zuckerman, Tsila
Fukushima, Kentaro
Vallejo, Juan Carlos
Pidala, Joseph
Hamad, Nada
Moiseev, Ivan
Bonifazi, Francesca
Apte, Shashikant
Langmuir, Peter
Hollaender, Norbert
Gowda, Maanasa
Stefanelli, Tommaso
Lee, Stephanie J.
Zeiser, Robert
Teshima, Takanori
BONE MARROW TRANSPLANTATION, 2021, 56 (SUPPL 1) : 74 - 76
[4] Biomarker and Safety Analyses of Patients With Steroid-Refractory Acute Graft-Vs-Host Disease Treated With Ruxolitinib or Best Available Therapy in the Randomized, Phase 3 REACH2 Study
不详
CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2021, 19 (02) : 10 - 12
[5] Biomarker Analysis in Patients (pts) with Steroid-Refractory Acute Graft-Vs-Host Disease (aGVHD) Treated with Ruxolitinib (RUX) or Best Available Therapy (BAT) in the Randomized, Phase 3 REACH2 Study
Socie, Gerard
Niederwieser, Dietger
Von Bubnoff, Nikolas
Mohty, Mohamad
Szer, Jeffrey
Or, Reuven
Butler, Jason P.
Wagner, Eva Maria
Forcade, Edouard
Caballer, Jaime Sanz
Russo, Domenico
Grillo, Giovanni
Zuckerman, Tsila
Bozdag, Sinem Civriz
Ritchie, David
Chaturvedi, Shalini
Prahallad, Anirudh
Sinclair, Karen
Wilke, Celine
Zeiser, Robert
BLOOD, 2020, 136
[6] Ruxolitinib Versus Best Available Therapy in Patients With Glucocorticoid-Refractory Chronic Graft-Vs-Host Disease: Primary Findings From the Phase 3, Randomized REACH3 Study
不详
CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2021, 19 (04) : 6 - 7
[7] Ruxolitinib (RUX) vs Best Available Therapy (BAT) in patients (pts) with Glucocorticoid-Refractory chronic Graft-vs-Host Disease (cGVHD): Primary findings from the phase 3, randomized REACH3 study
Zeiser, R.
Polverelli, N.
Ram, R.
Hashmi, S.
Chakraverty, R.
Langmuir, P.
Hollaender, N.
Gowda, M.
Stefanelli, T.
Lee, S. J.
Teshima, T.
Locatelli, F.
ONCOLOGY RESEARCH AND TREATMENT, 2021, 44 : 65 - 66
[8] Safety analysis of Ruxolitinib (RUX) vs Best Available Therapy (BAT) in patients (pts) with Steroid-Refractory (SR) acute Graft-vs-Host Disease (aGVHD) in the randomized phase 3 REACH2 study
von Bubnoff, N.
Butler, J.
Wagner, E.
Forcade, E.
Sanz, J.
Russo, D.
Grillo, G.
Zuckerman, T.
Bozdag, Civriz S.
Ayuk, F.
Stoelzel, F.
Yoon, S-S
Garcia-Gutierrez, V
Ritchie, D.
Bulabois, C-E
Rubio, M-T
Xu, J.
Morando, J.
Mahuzier, B.
Chandraiah, Mahadevaiah S.
Socie, G.
ONCOLOGY RESEARCH AND TREATMENT, 2021, 44 : 230 - 231
[9] Safety Analysis of Ruxolitinib (RUX) Vs Best Available Therapy (BAT) in Patients (pts) with Steroid-Refractory (SR) Acute Graft-Vs-Host Disease (aGVHD) in the Randomized Phase 3 REACH2 Study
Von Bubnoff, Nikolas
Butler, Jason P.
Wagner, Eva Maria
Forcade, Edouard
Caballer, Jaime Sanz
Russo, Domenico
Grillo, Giovanni
Zuckerman, Tsila
Bozdag, Sinem Civriz
Ayuk, Francis A.
Stoelzel, Friedrich
Yoon, Sung-Soo
Gutierrez, Jose Valentin Garcia
Ritchie, David
Bulabois, Claude-Eric
Rubio, Marie Therese
Xu, Judith
Morando, Juliane
Mahuzier, Bruyere
Chandraiah, Satish Mahadevaiah
Socie, Gerard
BLOOD, 2020, 136
[10] Ruxolitinib for steroid-refractory chronic graft-versus-host disease: Japanese subgroup analysis of REACH3 study
Shiratori, Souichi
Fukushima, Kentaro
Onishi, Yasushi
Doki, Noriko
Goto, Tatsunori
Okada, Masaya
Nakamae, Hirohisa
Maeda, Yoshinobu
Kato, Koji
Ishikawa, Takayuki
Kondo, Tadakazu
Toyosaki, Masako
Ikeda, Takashi
Uchida, Naoyuki
Maki, Akio
Shimada, Fumika
Tajima, Takeshi
Stefanelli, Tommaso
Teshima, Takanori
INTERNATIONAL JOURNAL OF HEMATOLOGY, 2024, 120 (06) : 705 - 716

← 1 2 3 4 5 →